We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best extremely profitable stocks to buy according to analysts. We recently ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (BMV:MEDP) with a Market Perform recommendation. Invesco holds 1,085K shares representing 3.56% ...

Leerink Partners analyst Geoff Porges maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) on Tuesday, setting a price target... Mizuho Securities analyst Salim Syed maintained a Buy rating on ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from Outperform to Market Perform. Analyst Price Forecast Suggests 2,468.35% ...